Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

HIV Infection

Free Subscription Articles published in J Med Virol Retrieve available abstracts of 78 articles: HTML format

Single Articles

April 2025
1. TADESE BK, You X, Ndao T, Tota JE, et al
   The Burden of HPV Infections and HPV-Related Diseases Among People With HIV: A Systematic Literature Review.
   J Med Virol. 2025;97:e70274.
   PubMed     Abstract available
   
   
   
2. BANGWEN E, Berens-Riha N, de Vrij N, Ceulemans A, et al
   No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients.
   J Med Virol. 2025;97:e70320.
   PubMed     Abstract available
   
   
   
3. WEI Q, Chen L, Yin Y, Pai M, et al
   Analysis of Blood Microbiome From People Living With HIV and Donors by 16S rRNA Metagenomic Sequencing.
   J Med Virol. 2025;97:e70341.
   PubMed     Abstract available
   
   
   
4. DEMIRDJIAN S, Naik V, Margot N, Falkard B, et al
   Phenotypic Characterization of Replication-Impaired Lenacapavir-Resistant HIV Clinical Isolates.
   J Med Virol. 2025;97:e70340.
   PubMed     Abstract available
   
   
   March 2025
5. JIANG Q, Zhou Z, Du X, Li Y, et al
   Novel Function of NUP153 in HNF4alpha Transcriptional Upregulation Contributes to Promoting HBV Replication.
   J Med Virol. 2025;97:e70256.
   PubMed     Abstract available
   
   
   
6. JIN Q, Zhou M, Sun M, Ning B, et al
   Global Temporal Trends in Mother-to-Child Transmission Disease Incidence Among Women of Child-Bearing Age: An Analysis of Global Burden of Disease Study 2021 Data.
   J Med Virol. 2025;97:e70283.
   PubMed     Abstract available
   
   
   
7. LIU S, Liu P, Lu Q, Shen Y, et al
   The Compensatory Effect of S375F on S371F Is Vital for Maintaining the Infectivity of SARS-CoV-2 Omicron Variants.
   J Med Virol. 2025;97:e70242.
   PubMed     Abstract available
   
   
   
8. AMEGASHIE EA, Kwayisi-Darkwah CK, Adusei-Poku M, Sikeola RO, et al
   Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co-infected With Human Coronaviruses in Ghana.
   J Med Virol. 2025;97:e70301.
   PubMed     Abstract available
   
   
   
9. SEBASTIAO CS, Bathy J, Nhampossa T, Santos A, et al
   Susceptibility to Lenacapavir Among Newly Diagnosed HIV-Positive Patients Followed Up in Mozambique That Presented With Primary Antiretroviral Resistance to Other Classes.
   J Med Virol. 2025;97:e70317.
   PubMed     Abstract available
   
   
   
10. ZHANG X, Wu S, Lin Y, Zhang W, et al
    Development of an Assay Evaluating the Inducible HIV-1 Latent Reservoir Based on Reverse Transcription Droplet Digital PCR for Unspliced/Intact Viral RNA.
    J Med Virol. 2025;97:e70295.
    PubMed     Abstract available
    
    
    
11. BETTUZZI T, Lebbe C, Grolleau C
    Modern Approach to Manage Patients With Kaposi Sarcoma.
    J Med Virol. 2025;97:e70294.
    PubMed     Abstract available
    
    
    February 2025
12. LUZ E, Marques M, Arriaga MB, Campos LM, et al
    Risk Factors for Viral Coinfections in Blood Donors in Bahia, Brazil.
    J Med Virol. 2025;97:e70186.
    PubMed     Abstract available
    
    
    
13. SILVESTRE C, Tuaillon E, Duroyon MM, Abrantes M, et al
    NK Count and Natural Cytotoxicity in Immune Nonresponders Versus Responders Living With HIV.
    J Med Virol. 2025;97:e70170.
    PubMed     Abstract available
    
    
    
14. SHARMA D, Rai M, Singh A, Gaur R, et al
    Fullerene (C(60) & C(70))-Meso-Tris-4-Carboxyphenyl Porphyrin Dyads Inhibit Entry of Wild-Type and Drug-Resistant HIV-1 Clades B and C.
    J Med Virol. 2025;97:e70181.
    PubMed     Abstract available
    
    
    
15. TYRBERG T, Hagberg L, Nilsson S, Grahn A, et al
    Incidence and Risk Factors for Varicella-Zoster Virus-Associated Central Nervous System Infections: A Nationwide Swedish Retrospective Case-Control Study.
    J Med Virol. 2025;97:e70166.
    PubMed     Abstract available
    
    
    
16. 
    Correction to "Fullerene (C60 & C70)-Meso-Tris-4-Carboxyphenyl Porphyrin Dyads Inhibit Entry of Wild-Type and Drug-Resistant HIV-1 Clades B and C".
    J Med Virol. 2025;97:e70232.
    PubMed    
    
    
    
17. LI K, Luo L, Ji Y, Zhang Q, et al
    Urgent Focus on the Surgical Risks of People Living With HIV: A Systematic Review and Meta-Analysis.
    J Med Virol. 2025;97:e70260.
    PubMed     Abstract available
    
    
    
18. HOTA M, Wondeu ALD, Abakar MF, Dezoumbe K, et al
    Integrated Seroprevalence and Genome-Based Study of SARS-CoV-2 Viral Strains in N'Djamena: Insights Into Chad's COVID-19 Epicenter.
    J Med Virol. 2025;97:e70234.
    PubMed     Abstract available
    
    
    
19. LU Z, Dong B, Yao P, Huang Y, et al
    Characteristics of Human Papillomavirus Prevalence and Infection Patterns Among Women Aged 35-65 in Fujian Province, China: A Nine-Year Retrospective Observational Study.
    J Med Virol. 2025;97:e70238.
    PubMed     Abstract available
    
    
    January 2025
20. XIAO Q, He S, Wang C, Liu Y, et al
    Urgent Call for Attention to HIV-Associated Lymphoma: After AIDS 2024, the 25th International AIDS Conference.
    J Med Virol. 2025;97:e70159.
    PubMed    
    
    
    
21. ZANET E, Taborelli M, Tirelli U, Diez-Martin J, et al
    Long-Term Clinical Outcomes After Autologous Hematopoietic Stem Cell Transplantation in 49 Individuals Living With HIV (PLWH) and Affected by High-Risk or Relapsed Lymphoma: A European Experience of Continued Relevance for PLWH.
    J Med Virol. 2025;97:e70165.
    PubMed     Abstract available
    
    
    December 2024
22. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed     Abstract available
    
    
    
23. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed     Abstract available
    
    
    
24. SHABIL M, Khatib MN, Ballal S, Bansal P, et al
    Effectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
    J Med Virol. 2024;96:e70122.
    PubMed     Abstract available
    
    
    
25. CHEN X, Chen R, Wen L, Qin T, et al
    Long Noncoding RNA LINC02453 Inhibits HIV-1 Replication by Binding With SEC13 to Regulate the Viral Productive Cycle.
    J Med Virol. 2024;96:e70116.
    PubMed     Abstract available
    
    
    
26. ZHANG J, Shao S, Chen X, Wang S, et al
    Genome-Wide Association Study of Persistent Anal Human Papillomavirus Infection Among HIV-Positive Males in Taizhou, China: A Cohort Study.
    J Med Virol. 2024;96:e70126.
    PubMed     Abstract available
    
    
    
27. LIN W, He Y, Gu F, Hu F, et al
    Hepatic Flare Following Effective Antiretroviral Therapy Is Associated With HBsAg Seroclearance in HBV/HIV-1 Co-Infection.
    J Med Virol. 2024;96:e70114.
    PubMed     Abstract available
    
    
    
28. CHEN F, Li D, Tang H, Ge L, et al
    Estimates of HIV Incidence, Prevalence, and Mortality in China 2018.
    J Med Virol. 2024;96:e70048.
    PubMed     Abstract available
    
    
    November 2024
29. GUIRAUD V, Naizet A, Khan H, Benhafoun G, et al
    Fourth-Generation HIV Rapid Tests: Enhanced Sensitivity and Reduced Diagnostic Window for HIV-1 Primary Infection Screening.
    J Med Virol. 2024;96:e70044.
    PubMed     Abstract available
    
    
    
30. LI X, Shi H, Shi H, Xu Y, et al
    Transmission Network and Phylogenetic Analysis Highlight the Role of Suburban Population in HIV-1 Transmission Among Older Adults in Nanjing, Jiangsu Province, China.
    J Med Virol. 2024;96:e70035.
    PubMed     Abstract available
    
    
    
31. LIU B, Zhang Q
    Systemic Immune-Inflammation-Based Biomarker and Fragility Fractures in People Living With HIV: A 10-Year Follow-Up Cohort Study in China.
    J Med Virol. 2024;96:e70052.
    PubMed     Abstract available
    
    
    
32. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed     Abstract available
    
    
    
33. ZHAO H, He Y, Ling X, Hou H, et al
    Profiles of Lymphocyte Subtypes in HIV-Infected People With Different Immunologic Responses to Antiretroviral Therapy.
    J Med Virol. 2024;96:e70081.
    PubMed     Abstract available
    
    
    October 2024
34. KUHN D, Heinen N, Sutter K, Herrmann ST, et al
    Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.
    J Med Virol. 2024;96:e29935.
    PubMed     Abstract available
    
    
    
35. LV S, Lan Y, He Y, Li Q, et al
    Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China.
    J Med Virol. 2024;96:e29937.
    PubMed     Abstract available
    
    
    
36. CHAIX ML, Terracol L, Nere ML, Stefic K, et al
    Susceptibility to lenacapavir, fostemsavir and broadly neutralizing antibodies in French primary HIV-1 infected patients in 2020-2023.
    J Med Virol. 2024;96:e29948.
    PubMed     Abstract available
    
    
    
37. ALIDJINOU EK
    Comments on "High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence".
    J Med Virol. 2024;96:e29950.
    PubMed    
    
    
    
38. ANDREATTA K, D'Antoni ML, Chang S, Parvangada A, et al
    High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence.
    J Med Virol. 2024;96:e29899.
    PubMed     Abstract available
    
    
    
39. VELLAS C, Doudou A, Mohamed S, Raymond S, et al
    Comparison of short-read and long-read next-generation sequencing technologies for determining HIV-1 drug resistance.
    J Med Virol. 2024;96:e29951.
    PubMed     Abstract available
    
    
    September 2024
40. LO VT, Lim HA, Jang SS, Kim MC, et al
    N121T and N121S substitutions on the SARS-CoV-2 spike protein impact on serum neutralization.
    J Med Virol. 2024;96:e29871.
    PubMed     Abstract available
    
    
    
41. GAY L, Desquiret-Dumas V, Nagot N, Rapenne C, et al
    Long-term persistence of mitochondrial dysfunctions after viral infections and antiviral therapies: A review of mechanisms involved.
    J Med Virol. 2024;96:e29886.
    PubMed     Abstract available
    
    
    
42. PAN D, Mohamed B, Gupta A, Arshad Z, et al
    Clinical and molecular epidemiology of enterovirus infections in cerebrospinal fluid samples, 2019-2023.
    J Med Virol. 2024;96:e29924.
    PubMed     Abstract available
    
    
    August 2024
43. LI J, Lv J, Yu F, Zhang Y, et al
    Temporal changes in plasma metabolic signatures to predict immune response of antiretroviral therapy among people living with HIV.
    J Med Virol. 2024;96:e29798.
    PubMed     Abstract available
    
    
    
44. MONTI B, Soria A, Saladini F, Lapadula G, et al
    Regaining virological suppression in a woman living with a six-class resistant HIV by combining injectable antiretroviral drugs guided by genotypic and phenotypic tests.
    J Med Virol. 2024;96:e29832.
    PubMed    
    
    
    
45. GUPTA A, Righi E, Konnova A, Sciammarella C, et al
    Interleukin-2-mediated CD4 T-cell activation correlates highly with effective serological and T-cell responses to SARS-CoV-2 vaccination in people living with HIV.
    J Med Virol. 2024;96:e29820.
    PubMed     Abstract available
    
    
    
46. SUTERIO DG, Hunter JR, Tenore SB, Pimentel SR, et al
    People living with HIV co-infected with the Kaposi Sarcoma-associated Herpes Virus have a distinct HIV Tat profile and higher rates of antiretroviral virologic failure, more evident among those with Kaposi's sarcoma.
    J Med Virol. 2024;96:e29840.
    PubMed     Abstract available
    
    
    
47. HEHE Z, Minna Z, Qin F, Tielin N, et al
    Application of molecular epidemiology in revealing HIV-1 transmission network and recombination patterns in Tianjin, China.
    J Med Virol. 2024;96:e29824.
    PubMed     Abstract available
    
    
    
48. WANG Z, Wang W, Gao Z, Gao H, et al
    Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles.
    J Med Virol. 2024;96:e29830.
    PubMed     Abstract available
    
    
    
49. PIETROLUONGO E, Luciano A, Peddio A, Buonaiuto R, et al
    Exploring the interplay between Kaposi's sarcoma and SARS-CoV-2 infection: A case series and systematic review.
    J Med Virol. 2024;96:e29849.
    PubMed     Abstract available
    
    
    
50. RIZZO A, Moschese D, Salari F, Giacomelli A, et al
    Anal HPV prevalence in individuals with and without other concomitant sexually transmitted infections.
    J Med Virol. 2024;96:e29852.
    PubMed     Abstract available
    
    
    
51. PASSERINI S, Fracella M, Benvenuto D, Bugani G, et al
    High rates of anal Merkel Cell Polyomavirus and HPV co-infection among people living with HIV.
    J Med Virol. 2024;96:e29883.
    PubMed     Abstract available
    
    
    
52. FOURY A, Saunier A, Taverniers A, Pinet N, et al
    The relevance of ultradeep sequencing for low HIV-1 viral loads and proviruses in the clinical setting.
    J Med Virol. 2024;96:e29870.
    PubMed     Abstract available
    
    
    July 2024
53. MCCLURE CP, Kean K, Reid K, Mayne R, et al
    Reconstruction of the historic time course of blood-borne virus contamination of clotting factor concentrates, 1974-1992.
    J Med Virol. 2024;96:e29774.
    PubMed     Abstract available
    
    
    
54. LIANG Z, Lin C, Huo D, Yang Y, et al
    First detection of multiple cases related to CV-A16 strain of B1c clade in Beijing in 2022.
    J Med Virol. 2024;96:e29796.
    PubMed     Abstract available
    
    
    
55. FANG T, Liu L, Mao S, Jiang Z, et al
    Association between virus infection and periodontitis: Evidence from the National Health and Nutrition Examination Survey 2009-2014.
    J Med Virol. 2024;96:e29784.
    PubMed     Abstract available
    
    
    
56. ZHANG Y, Geng M, Xing Y, Ren X, et al
    Improvement and exacerbation of multiple disparities in sexually transmitted infections among children and adolescents aged 6-22 years: An analysis of national surveillance data from 2013 to 2021.
    J Med Virol. 2024;96:e29808.
    PubMed     Abstract available
    
    
    
57. MATSCHKE J, Hartmann K, Pfefferle S, Wang Y, et al
    Inefficient tissue immune response against MPXV in an immunocompromised mpox patient.
    J Med Virol. 2024;96:e29811.
    PubMed     Abstract available
    
    
    
58. YAN H, Wu H, Li S, Wang J, et al
    The origin and spread of HIV-1 CRF59_01B epidemic in China: A molecular network and phylogeographic analysis.
    J Med Virol. 2024;96:e29799.
    PubMed     Abstract available
    
    
    June 2024
59. LI J, Xie DD, Cui HL, Yue C, et al
    Trends in the burden and determinants of HIV in the Asia-Pacific region (1990-2019): An age-period-cohort analysis of the 2019 Global Burden of Disease Study.
    J Med Virol. 2024;96:e29724.
    PubMed     Abstract available
    
    
    
60. CHEN R, Fu Y, Li D, Wang S, et al
    Proteomic analysis of plasma in healthy adults receiving recombinant vaccinia virus provides novel insights into HIV-1 neutralizing antibodies.
    J Med Virol. 2024;96:e29749.
    PubMed     Abstract available
    
    
    
61. MOOKO T, Bisiwe FB, Chikobvu P, Morobadi MD, et al
    The prevalence of HIV resistance mutations and their influence on the shedding of HIV-1 into peritoneal dialysis effluent.
    J Med Virol. 2024;96:e29734.
    PubMed     Abstract available
    
    
    
62. GU F, Zeng K, Lan X, He Y, et al
    Measuring HBV pregenomic RNA may be a potential biomarker to determine HBV functional cure in HIV/HBV-co-infected patients with HBsAg loss.
    J Med Virol. 2024;96:e29762.
    PubMed     Abstract available
    
    
    May 2024
63. LIRA GS, Ota VA, Melo MQS, Castineiras ACP, et al
    Mpox outbreak in Rio de Janeiro, Brazil: A translational approach.
    J Med Virol. 2024;96:e29621.
    PubMed     Abstract available
    
    
    
64. RALLON N, Jimenez-Carretero D, Restrepo C, Ligos JM, et al
    A specific natural killer cells phenotypic signature associated to long term elite control of HIV infection.
    J Med Virol. 2024;96:e29646.
    PubMed     Abstract available
    
    
    
65. MATUSALI G, Mazzotta V, Meschi S, Colavita F, et al
    JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.
    J Med Virol. 2024;96:e29631.
    PubMed    
    
    
    
66. RZYMSKI P, Zarebska-Michaluk D, Parczewski M, Genowska A, et al
    The burden of infectious diseases throughout and after the COVID-19 pandemic (2020-2023) and Russo-Ukrainian war migration.
    J Med Virol. 2024;96:e29651.
    PubMed     Abstract available
    
    
    
67. HWANG JH, Hwang JH
    Is a 2-week regimen of tecovirimat sufficient for the treatment of Mpox (monkeypox) in advanced HIV patients with a low CD4 cell count?
    J Med Virol. 2024;96:e29617.
    PubMed    
    
    
    April 2024
68. KIM M, Kim E
    Effective vaccination strategies for human papillomavirus (HPV) infection and cervical cancer based on the mathematical model with a stochastic process.
    J Med Virol. 2024;96:e29558.
    PubMed     Abstract available
    
    
    
69. JIANG X, Gao Z, Sharma PP, Kumar S, et al
    Discovery of low-molecular-weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability.
    J Med Virol. 2024;96:e29594.
    PubMed     Abstract available
    
    
    
70. MATUSALI G, Vergori A, Cimini E, Mariotti D, et al
    Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
    J Med Virol. 2024;96:e29598.
    PubMed     Abstract available
    
    
    
71. LI Y, Zhang X, Huang Y, Gao L, et al
    The prevalence of Human Immunodeficiency Virus infection among voluntary blood donors in mainland China: A systematic review and meta-analysis.
    J Med Virol. 2024;96:e29599.
    PubMed     Abstract available
    
    
    March 2024
72. XIAO J, Luo Y, Li Y, Yao X, et al
    The characteristics of BCR-CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccinated volunteers.
    J Med Virol. 2024;96:e29488.
    PubMed     Abstract available
    
    
    
73. XIE M, Wang Z, Zhao F, Li Y, et al
    Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles.
    J Med Virol. 2024;96:e29502.
    PubMed     Abstract available
    
    
    
74. CORMA-GOMEZ A, Cabello A, Orviz E, Morante-Ruiz M, et al
    Long or complicated mpox in patients with uncontrolled HIV infection.
    J Med Virol. 2024;96:e29511.
    PubMed     Abstract available
    
    
    
75. WANG Z
    Novel diarylpyrimidine subtypes as HIV-1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile.
    J Med Virol. 2024;96:e29553.
    PubMed    
    
    
    
76. TRUNFIO M, Tang B, Okwuegbuna O, Iudicello JE, et al
    Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers.
    J Med Virol. 2024;96:e29550.
    PubMed     Abstract available
    
    
    
77. FARAONE JN, Wang X, Qu P, Zheng YM, et al
    Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
    J Med Virol. 2024;96:e29520.
    PubMed     Abstract available
    
    
    
78. KASSAM P, El-Zein M, Laurie C, Tota JE, et al
    Use of a carrageenan-based gel had no impact on anal HPVs 16 and 18 viral loads in gay, bisexual, and other men who have sex with men.
    J Med Virol. 2024;96:e29562.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.